ArticleJAMA network open2020
Statins and LDL-C in Secondary Prevention-So Much Progress, So Far to Go.
Article in JAMA network open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management.BMC cardiovascular disorders · 2026Pooled it
- Guideline
- Evolving paradigms in the management of dyslipidemia: comparison between the 2019 ESC/EAS guidelines and the 2025 focus update.Internal and emergency medicine · 2026Review
- Intensive Lipid-Lowering Therapy Following Acute Coronary Syndrome: The Earlier the Better.Journal of cardiovascular development and disease · 2025Review
- Safety and Effectiveness of Pravastatin in Korean Patients with Dyslipidemia Based on the Cardiovascular Risk Classification: Pooled Analysis of Four Observational Studies.Endocrinology and metabolism (Seoul, Korea) · 2025Observational
- Observational
- Analysis of Personalized Cardiovascular Drug Therapy: From Monitoring Technologies to Data Integration and Future Perspectives.Biosensors · 2025Review
- Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.International journal of molecular sciences · 2025Review
- Learnings from Implementation Strategies to Improve Lipid Management.Current cardiology reports · 2025Review
- Predictors and benefits of lipid-lowering therapy initiation after an atherosclerotic cardiovascular event: a retrospective cohort study.Frontiers in pharmacology · 2025Article
- Lp(a): A Rapidly Evolving Therapeutic Landscape.Current atherosclerosis reports · 2024Review
- Hepatitis C Infection Is Not a Cardiovascular Risk Factor in Young Adults.Biomedicines · 2024Article
- Article
- Article
- Lipid-lowering agent preferences among patients with hypercholesterolemia: a focus group study.Journal of pharmaceutical policy and practice · 2024Article
- Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL-ACS Data.Journal of the American Heart Association · 2023Observational
- A look to the past - what has had the biggest impact on lipids in the last four decades? A personal perspective.Archives of medical science : AMS · 2023Article
- Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).Journal of cachexia, sarcopenia and muscle · 2022Review
- 2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy.Archives of medical science : AMS · 2022Article
- CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities.Metabolites · 2021Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
33216137What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.